RxDoctor Payments Data

Camille Pousson, MD

Psychiatry · Killean, TXNPI 1144265653

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 94 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$499
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$269
  • Neurocrine Biosciences, Inc.$194
  • AbbVie$182
  • Johnson & Johnson$162
  • Otsuka America Pharmaceutical, Inc.$89
  • plus $169 from 5 others

What the payments were for

  • Food & beverage$1,33986%
  • Education$22714%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,565 in reported general payments places this provider in the 75th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$5,869
Medicare patients
26
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$279,303
Invega SustennaPaliperidone Palmitate30$112,473
Risperidone ErRisperidone Microspheres13$21,500
CaplytaLumateperone Tosylate13$20,741
RexultiBrexpiprazole12$20,423
Aripiprazole149$8,386
Ziprasidone Hcl92$6,639
Quetiapine Fumarate237$4,254
Divalproex Sodium ErDivalproex Sodium104$3,331
Lurasidone Hcl11$2,983
Prazosin Hcl87$1,086
Haloperidol Decanoate14$1,047
Benztropine Mesylate77$1,034
Propranolol Hcl63$1,017
Buspirone Hcl58$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$194$279,30334 claims
Johnson & JohnsonInvega Sustenna$162$112,47330 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$269$20,74113 claims
Otsuka America Pharmaceutical, Inc.Rexulti$89$20,42312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Killean

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →